REDWOOD CITY, Calif. & BOSTON - Adicet Bio, Inc. (NASDAQ:ACET), a biotechnology company focused on the development of gamma delta T cell therapies, has announced the initiation of a Phase 1 clinical trial with the first patient dosed for a potential treatment of metastatic/advanced clear cell renal cell carcinoma (ccRCC). The company anticipates sharing early-stage clinical data from this trial in the first half of 2025.
The trial is an open-label study designed to assess the safety, tolerability, and preliminary anti-tumor activity of ADI-270, an allogeneic gamma delta CAR T cell therapy candidate. Patients with relapsed or refractory metastatic/advanced ccRCC will be administered a single dose of ADI-270 following lymphodepletion, with the possibility of a second dose contingent on meeting specific criteria. The trial will evaluate the overall response rate, duration of response, and disease control rate. With a market capitalization of just $73.78 million and a price-to-book ratio of 0.35, the company maintains a strong liquidity position with a current ratio of 10.64, according to InvestingPro data.
ADI-270 targets CD70-positive cancers and is engineered with a third-generation CAR, using CD27 as the binding moiety. It incorporates a dominant negative form of the transforming growth factor-β receptor II to counteract the immunosuppressive tumor microenvironment. This therapy is designed to enhance exposure and persistence while reducing susceptibility to host vs. graft elimination.
ccRCC, the most prevalent form of kidney cancer, is known for its aggressive nature and potential to metastasize to various organs. Despite the high survival rate for localized RCC, advanced cases have a five-year survival rate of only 15%. The initiation of this trial represents a step forward in addressing the urgent need for effective treatments for patients with advanced ccRCC.
Adicet Bio is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to potentially improve clinical outcomes for cancer patients. The company's approach reflects a broader trend in biotechnology to develop targeted and more personalized treatments for cancer.
This press release contains forward-looking statements regarding the clinical development of ADI-270 and its potential as a treatment for solid tumors and ccRCC. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. The company has cautioned that positive preclinical study results may not be indicative of clinical trial outcomes. For deeper insights into Adicet Bio's financial health, valuation metrics, and 12 additional ProTips, investors can access the comprehensive Pro Research Report available on InvestingPro, part of their coverage of over 1,400 US equities.
For more information on the clinical trial or ADI-270, interested parties may contact Adicet Bio. This article is based on a press release statement from the company.
In other recent news, biotechnology company Adicet Bio, Inc. has made significant strides in its financial and clinical operations. The company has appointed Dr. Julie Maltzman as its new Chief Medical (TASE:PMCN) Officer, bringing over two decades of experience in drug development. Adicet Bio also successfully cleared its debt with Banc of California (NYSE:BANC) and amended its loan agreement with Pacific Western Bank, providing more flexibility in managing its financial resources and investments in its Shanghai subsidiary.
On the clinical front, Adicet Bio initiated a Phase 1 trial for its CAR T cell therapy, ADI-270, targeting advanced clear cell renal cell carcinoma. The company has also commenced a Phase 1 clinical trial for lupus nephritis patients and received approval from the FDA to expand this trial to include idiopathic inflammatory myopathy and stiff person syndrome.
These developments have led to positive feedback from analysts, with Guggenheim maintaining a Buy rating and H.C. Wainwright holding a Neutral stance. Canaccord Genuity and Jones Trading have also adjusted their price targets for Adicet Bio. Lastly, the company expanded its board with the appointment of Dr. Lloyd Klickstein, an expert in rheumatology, immunology, and drug development. These are the recent developments for Adicet Bio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.